RT Journal Article
SR Electronic
T1 In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.04.24306824
DO 10.1101/2024.05.04.24306824
A1 Cortés, Adriana
A1 Phung, Toan K.
A1 de Mena, Lorena
A1 Garrido, Alicia
A1 Infante, Jon
A1 Ruíz-Martínez, Javier
A1 Galmés-Ordinas, Miquel À.
A1 Glendinning, Sophie
A1 Pérez, Jesica
A1 Roig, Ana
A1 Soto, Marta
A1 Cosgaya, Marina
A1 Ravasi, Valeria
A1 Fernández, Manel
A1 Rubiano-Castro, Alejandro
A1 Díaz, Ramón
A1 Hernández-Eguiazu, Haizea
A1 Sánchez-Quintana, Coro
A1 Vinagre-Aragón, Ana
A1 Mondragón, Elisabet
A1 Croitoru, Ioana
A1 Rivera-Sánchez, María
A1 Corrales-Pardo, Andrea
A1 Sierra, María
A1 Tolosa, Eduardo
A1 Malagelada, Cristina
A1 Nirujogi, Raja S.
A1 Fernández-Irigoyen, Joaquín
A1 Santamaría, Enrique
A1 Alessi, Dario R.
A1 Martí, María J.
A1 Ezquerra, Mario
A1 Fernández-Santiago, Rubén
YR 2024
UL http://medrxiv.org/content/early/2024/05/06/2024.05.04.24306824.abstract
AB Leucine-rich repeat kinase 2 (LRRK2) inhibition is a promising disease-modifying therapy for LRRK2-associated Parkinson’s disease (L2PD) and idiopathic PD (iPD). Yet, pharmaco-dynamic readouts and progression biomarkers for disease modification clinical trials are insufficient. Employing phospho-/proteomic analyses we assessed the impact that LRRK2 activating mutations had in peripheral blood mononuclear cells (PBMCs) from a LRRK2 clinical cohort from Spain (n=174) encompassing G2019S L2PD patients (n=37), non-manifesting LRRK2 mutation carriers of G2019S, here, G2019S L2NMCs (n=27), R1441G L2PD patients (n=14), R1441G L2NMCs (n=11), iPD (n=40), and controls (n=45). We identified 207 differential proteins in G2019S L2PD compared to controls (39 up/ 168 down) and 67 in G2019S L2NMCs (10 up/ 57 down). G2019S down-regulated proteins affected the endolysosomal pathway, proteostasis and mitochondria, e.g., ATIC, RAB9A, or LAMP1. At the phospho-proteome level, we observed increases in endogenous phosphorylation levels of pSer106 RAB12 in G2019S carriers, which were validated by immunoblotting after 1 year of follow-up (n=48). Freshly collected PBMCs from 3 G2019S L2PD, 1 R1441G L2PD, 1 iPD, and 5 controls (n=10) showed strong diminishment of pSer106 RAB12 phosphorylation levels after in-vitro administration of the MLi-2 LRRK2 inhibitor. Using machine learning, we identified an 18-feature G2019S phospho-/protein signature capable of discriminating G2019S L2PD, L2NMCs, and controls with 96% accuracy that correlated with disease severity, i.e., UPDRS-III motor scoring. Our study identified pSer106 RAB12 as an endogenous biomarker in easily accessible PBMCs from G2019S carriers and suggests that phospho-/proteomic findings in human PBMCs such as pSer106 RAB12 can be deployed as a universal pharmaco-dynamic readout for L2PD, L2NMCs, and iPD. Future work may determine whether pSer106 RAB12 could help with patient enrichment and monitoring drug efficacy in LRRK2 clinical trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Michael J. Fox Foundation for Parkinson Research (MJFF) (MJFF 000858) to RFS, ME, CM, ES, JI, and JRM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Probands participated in the study after local ethics approval and signed informed consent. The overall study was approved by the Ethical committee of the Hospital Clinic of Barcelona (code HCB/2020/1238).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWe provide full open access to all data generated here through the information included in this article and the open Curtain software. https://curtain.proteo.info/#/ce36322f-b1ef-4ee6-b454-6ffd5c8a0429 https://curtain.proteo.info/#/e97b6761-dbe3-41cb-8b3d-4ab9f2c93aba PBMCsPeripheral blood mononuclear cellsCNSCentral nervous systemDIAData independent acquisitionMSMass-spectrometryPDParkinson’s diseaseLRRK2Leucine-rich repeat kinase 2L2PDLRRK2-associated PD patientsL2NMCsNon-manifesting LRRK2 mutation carriersiPDIdiopathic PD patientspPhospho-FCFold-change